aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
From TechCrunch
By Marina Temkin
June 8, 2024
Anterior, a company that uses AI to expedite health insurance approval for medical procedures, has raised a $20 million Series A round at a $95 million post-money valuation led by NEA, according to two people familiar with the deal. Existing investors Sequoia, which led Anterior’s $3.2 million seed round last September, and Neo, an accelerator that helped the company launch in the summer of 2022, also participated in the Series A financing.
The round also included a host of angel investors, including Mustafa Suleyman, a DeepMind and Inflection AI co-founder who was hired by Microsoft in March to lead the tech giant’s consumer AI division.
NEA and Anterior didn’t immediately respond to a request for comment.
Anterior, formerly known as Co:helm, was co-founded by Abdel Mahmoud, a former doctor who left medicine to pursue a master’s degree in computer science and a career in tech after he grew frustrated with the amount of time he spent on administrative functions rather than with patience.
The company has built an LLM-powered co-pilot that helps nurses and doctors save hours on gathering medical documentation required by insurance. Anterior’s solution aims to reduce denial rates and accelerate patient access to care.
While Anterior’s initial offering is in prior authorization automation, the company eventually plans to expand into other medical administrative functions.
Mohamad Makhzoumi, managing general partner on NEA’s healthcare team and co-CEO of the firm, joined Anterior’s board. Makhzoumi’s investments include Tempus, a genomic testing and data analysis company founded by Groupon founder Eric Lefkofsky, which is planning to IPO next week at a valuation of up to $6.1 billion. Makhzoimi also backed Xaira, an AI drug discovery startup that launched this year with $1 billion in funding.
Anterior competes with Cohere Health, another provider of prior authorization automation, which raised a $50 million round in February led by Deerfield Management, with participation from Define Ventures, Flare Capital Partners, Longitude Capital and Polaris Partners, bringing the five-year-old company’s total funding to $106 million.
Share:
Bench is charging people for services they already paid for, some customers say
After Employer.com acquired bankrupt accounting startup Bench in a fire-sale late last year, CEO Jesse Tinsley pledged on LinkedIn and elsewhere to honor past customer payments. “We’re honoring all prepaid Bench services even though we will not have the revenue from that directly ourselves,” Tinsley said in an interview with founder and investor Julian Weisser. But some Bench customers say they’re being charged to get books or tax returns they previously paid for. A lawsuit filed on Tuesday by
Mar 14, 2025
Profitable Klarna files for a potentially blockbuster IPO
Swedish fintech Klarna took the next step in its highly anticipated U.S. IPO on Friday when it made its F-1 prospectus public. We are sifting through the document now. Klarna hopes to raise at least $1 billion at a $15 billion valuation with this IPO, Bloomberg reported last week. The public documents don’t yet reveal how many shares it plans to sell or the price range, so we won’t know if this IPO will meet its fundraising aspirations or not until it prices shares. That’s typically around a mo
Mar 14, 2025
Tern AI’s low-cost GPS alternative actually works
We’ve all experienced that moment of frustration when the GPS glitches and you miss an exit on the highway. The team at Tern AI, which is building a low-cost GPS alternative, says that’s because the current technology is limited by its reliance on satellite positioning. Tern AI says it has figured out how to locate the position of a vehicle using only map information and a vehicle’s existing sensor data. The company’s pitch: It’s a cheap system that doesn’t require any additional expensive sen
Mar 14, 2025
Don't miss our latest news and updates. Subscribe to the newsletter